hepatic tumor requiring surgical resection
Conditions
Interventions
Percutaneous marking for liver tumor Transcatheteratic marking for liver tumors
Sponsors
Hiroshima University Hospital Department of gastroenterological surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patient scheduled for diagnosis for liver tumor. 2. Patient who is scheduled for hepatectomy for hepatic tumor. 3. Patient whose Performance Status (PS) of the Eastern Cooperative Oncology Group (ECOG) is 0 - 1. 4. Male or female aged 20 years or older at the time of acquiring consent (no outpatient or hospitalization is acceptable). 5. Patients who have obvious tumorous lesions in the liver due to various imaging tests such as CT and MRI. Although the number of tumors is not specified, only one tumor to be marked is 20 mm or less in diameter. 6. Patient who satisfies the following criteria in the blood test at the time of registration, and retains the functions of major organs (bone marrow, liver, kidney, lung, etc.). A) Leukocyte count: 2,000 / mm 3 or more B) Hemoglobin content: not less than 8.0 g / dl C) Number of platelets: 50,000 / mm 3 or more D) Total bilirubin: 3.0 mg / dl or less E) eGFR: 60 ml / min / 1.73 m 3 or more (In case of falling below, decide on pretreatment and treatment in accordance with the provision of "Angiography examination IVR for patients with impaired renal function" in the hospital. 7. Patient who has sufficient judgment ability to understand the research contents and obtained written consent for participation of this study. 8. Patient who can withdraw anticoagulant on the day of marking.
Exclusion criteria
Exclusion criteria: 1. Patients with severe (NYHA class III or more) ischemic heart disease. 2. Patient who complicated of severe liver cirrhosis (hepatopathy degree C). 3. Patients with dyspnea requiring oxygen administration due to interstitial pneumonia, pulmonary fibrosis and others. 4. Patients who are undergoing dialysis with chronic renal failure. 5. Patients currently suffering from duplicated cancer of active activity. 6. Patients who are judged to be difficult to participate in research due to psychosis or psychiatric symptoms. 7. Other patients who are deemed inappropriate for the research researcher or research sharing doctor to conduct this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| After marking, CT, ultrasound marker and tumor visibility (visible / impossible) Visibility (markable / impossible) of markers and tumor at hepatectomy Percentage of completion of markers and tumor resection Measurement of final marker and tumor distance | — |
Secondary
| Measure | Time frame |
|---|---|
| Complications during marking Surgery results Postoperative liver dysfunction Postoperative complication | — |
Countries
Japan
Contacts
Public ContactShintaro Kuroda
Hiroshima University Hospital Department of gastroenterological surgery
Outcome results
None listed